参考文献/References:
[1] Murray CJ,Atkinson K,Bhalla G,et al.The state of US health,1999～2010:burden of diseases,injuries,and risk factors[J].JAMA,2013,310(6):591-608.
[2] Lees AJ,Hardy J,Revesz T.Parkinson's disease[J].Lancet,2009,373(9680):2055-2066.
[3] Faberqvist T,Bergstrom J,Lannfelt L,et al.Immunotherapy targeting a-synuclein,with relevance for future treatment of Parkinson's disease and other Lewy body diso-rders[J].Immunotherapy,2014,6(2):141-153.
[4] Rascol O,Lozano A,Stern M,et al.Milestones in parkinson's disease therapeutics[J].Movement Disorders,2011,26(6):1072-1082.
[5] 焦怡琳,王吉春,何广学.中国在精准医学领域面临的机遇与挑战[J].中国公共卫生管理,2015,31(5):601-603.
[6] Goldman SM.Environmental toxins and Parkinson's disease[J].Annu.Rev.Phannacol.Toxicol,2014,54(3):141-164.
[7] Montine TJ,Montine KS.Precision medicine:Clarity for the clinical and biological c-omplexity of Alzheimer's and Parkinson[J].s diseases.J.Exp.Med,2015,212(5):601-605.
[8] Verstraeten A,Theuns J,Broeckhoven CV.Progress in unraveling the genetic etiol-ogy of Parkinson disease in a genomic era[J].Trends Genet,2015,31(3):140-149.
[9] Roe CM,Fagan E,Grant J,et al.Amyloid imaging and CSF biomarkers in predicti-ng cognitive impairment up 2 to 7.5 years later[J].Neurology,2013,80(19):1784-1791.
[10] Strauss I,Kalia SK,Lozano AM.Where are we with surgical therapies for Parkinso-n's disease? [J].Parkinsonism Relat Disord,2014,20(1):187-191.
[11] Kiely AP,Asi YT,Kara E,et al.Alpha-synucleinopathy associated with G51D SNCA mutation:a Link between Parkinson's disease and multiple system atrophy? [J].Acta Neur-oPatbol,2013,125(5):753-769.
[12] Appel-Cresswell S,Vilarino-Guell C,Encarnacion M,et al.Alpha-synuclein p[J].H50Q,a novel pathogenic mutation for Parkinson's disease.Mov.Disord,2013,28(6):811-813.
[13] 赵晓宇,刁天喜,高云华,等.标题为空[J].“精准医学计划”解读与思考.军事医学,2015,39(4):241-244.
[14] 杨焕明.对奥巴马版“精准医学”的“精准”解读[J].西安交通大学学报,2015,36(6):721-723.